Mobile

A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitab...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005746-36

A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitabine Therapy (Gemzar)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to assess the efficacy of AZD6244 versus capecitabine in the treatment of advanced or metastatic pancreatic cancer by assessment of time to death (TTD).

Critère d'inclusion

  • Advanced or Metastatic Pancreatic Cancer

Liens